KRAS4A can interact with Hexokinase 1 and relieve glucose-6-phosphate-dependent allosteric inhibition of Hexokinase 143 possibly enabling Hexokinase 1 to be a stronger driver of glucose consumption than Hexokinase 2 in certain cancers. Here, HK2 is linked to cancer.